Hedge Fund's New Patent Attack Targets Biogen's MS Drug
An organization tied to superstar hedge fund head Kyle Bass on Wednesday filed its latest challenge of a drug patent, urging the Patent Trial and Appeal Board to nix a patent...To view the full article, register now.
Already a subscriber? Click here to view full article